Thromboelastography, Cytokines and HLA-antibodies in Patients With Chemotherapy-induced Thrombocytopenia
This is a prospective observational clinical study to characterise abnormalities of thromboelastography (TEG) parameters in patients with chemotherapy-induced thrombocytopenia. The investigators are also studying the influence of cytokines on bleeding and of HLA-antibodies on effect of platelet transfusion in the patient group mentioned.
The investigators' hypothesis is that changes in TEG-parameters reflect the patients tendency to bleed.
Bone Marrow Diseases
|Study Design:||Time Perspective: Prospective|
|Official Title:||Thromboelastography, Cytokines and HLA-antibodies in Patients With Chemotherapy-induced Thrombocytopenia|
- Thromboelastography [ Time Frame: 2 years ] [ Designated as safety issue: No ]To characterise changes in TEG-parameters in patients with chemotherapy-induced thrombocytopenia
- Cytokines [ Time Frame: 2 years ] [ Designated as safety issue: No ]To investigate cytokine profiles in patients with and without bleeding with the aim of identifying risk factors of bleeding in patients with chemotherapy-induced thrombocytopenia
- Bleeding [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To investigate the relationship between TEG-parameters, bleeding and need for platelet transfusion.
To investigate the influence of HLA antibodies on risk of bleeding and transfusion complications.
Biospecimen Retention: Samples Without DNA
Plasma specimens are kept frozen.
|Study Start Date:||June 2013|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01928017
|Contact: Elin N Opheim, firstname.lastname@example.org|
|Contact: Tor A Hervig, email@example.com|
|Haukeland University Hospital||Recruiting|
|Bergen, Norway, 5021|
|Contact: Elin N Opheim, cand.med 004755973044 firstname.lastname@example.org|
|Contact: Torunn O Apelseth, dr. med 004755973092 email@example.com|
|Principal Investigator: Elin N Opheim, cand.med|
|Study Director:||Tor A Hervig, dr.med||University of Bergen|